Immutep (IMMP) said Tuesday it secured a new patent from the US Patent and Trademark Office covering methods for the treatment of cancer by administering eftilagimod alfa in combination with an antibody.
The patent, entitled "Combined Preparations for the Treatment of Cancer or Infection," expires Jan. 20, 2036, the company said.
Immutep shares were 1.9% higher in premarket trading.